Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients

Keyphrases

• Heart Failure Patients 100%
• Acute Decompensated Heart Failure 100%
• Inotropic Therapy 100%
• Levosimendan 100%
• Milrinone 100%
• B-natriuretic Peptide 36%
• Quality of Life 18%
• Echocardiography 18%
• Heart Failure 18%
• Maximal O2 Consumption 18%
• Placebo 9%
• Quality of Life Improvement 9%
• Quality of Life Questionnaire 9%
• Heart Failure Hospitalization 9%
• Outpatient Clinic 9%
• Left Ventricular Ejection Fraction 9%
• New York Heart Association Class 9%
• Two-point 9%
• Definitive Treatment 9%
• Multicenter Cohort Study 9%
• Test Failure 9%
• Once-weekly 9%
• 4-cycle 9%
• Heart Failure Clinic 9%
• Annular Velocity 9%
• Ambulatory Heart Failure 9%
• Right Ventricular Systolic Function 9%
• EQ-5D-5L Questionnaire 9%
• Lack of Evidence 9%
• Guideline-directed Medical Therapy 9%
• Cardiopulmonary Exercise Test 9%

Medicine and Dentistry

• Congestive Heart Failure 100%
• Inotropism 100%
• Milrinone 100%
• Levosimendan 100%
• Quality of Life 36%
• Natriuretic Factor 36%
• Echocardiography 18%
• Oxygen Consumption 18%
• Outpatient 9%
• Placebo 9%
• Systolic Function 9%
• Heart Left Ventricle Ejection Fraction 9%
• Cardiopulmonary Exercise Test 9%
• New York Heart Association Class 9%